Renzenbrink & Partner has advised Klingel-medical metal Group (“Klingel medical metal”), a portfolio company of IK VIII Fund (“IK”), on the acquisition of Ruetschi Technology Holding AG (“Ruetschi”). Ruetschi is a leading Swiss full-service provider of sterile packaged disposable medical devices with a special focus on orthopaedics and spine surgery. The companies of the Ruetschi Group are headquartered in Muntelier, Switzerland. Ruetschi operates further sites in Yverdon-les-Bains (Switzerland) and Renquishausen (Germany) and employs more than 200 people. <\/p>\n\n
With the acquisition of Ruetschi, Klingel medical metal, with over 600 employees worldwide, is adding further production capacities and leading MedTech customers to its established platform in Switzerland.<\/p>\n\n
Renzenbrink & Partner advised IK on the acquisition of Klingel medical metal in 2018 and was subsequently in charge of two add-on acquisitions in Switzerland (Gehring Cut AG and B\u00e4chler Feintech AG) and one German add-on (Puracon GmbH).<\/p>\n\n
Renzenbrink & Partner advised Klingel medical metal on the acquisition of Ruetschi with a team consisting of partners Dr. Niels Maier<\/a>, Dr. Ulf Renzenbrink<\/a> (both Corporate\/PE) and Marc H. Kotyrba<\/a> (Tax\/PE) as well as counsel Christopher Blumenthal<\/a> and associates Dr. Alexander Haunschild<\/a> (both Corporate\/PE) and Marie Eikmeier<\/a> (Tax\/PE) in connection with all German corporate and tax aspects of the transaction (including a re-investment). Wenger & Vieli AG advised Klingel medical metal on all corporate and tax aspects of the transaction under Swiss law. <\/p>\n","protected":false},"featured_media":890,"template":"","class_list":["post-892","deals","type-deals","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n